Chapter 9: The Patient Who Lived
The letter arrived at 12:43 in the morning.
By then, the celebration had become an overnight board session. Caterers carried away untouched desserts while lawyers arrived through a service entrance. Outside, reporters waited beneath the atrium lights.
Rhea read the sender's name and stopped.
That frightened me more than the patent fight.
"What is it?"
She turned her phone facedown. "A communication from counsel for a former study participant."
Celeste immediately looked toward Nathan.
"Which participant?" the audit chair asked.
"I need permission to identify the client within this meeting."
Rhea stepped away to call the attorney. She returned four minutes later with a narrow authorization: name, the existence of a written inquiry, and nothing about current health beyond what the client had chosen to state.
She looked at me before she spoke.
"Leah Morgan."
The table disappeared.
For five years, I had known Leah as Participant 014 in sealed reports and as the woman whose serious reaction ended every conversation about my work. Sterling told me privacy rules prevented direct contact. Then they revoked my access, issued their findings, and made my name the explanation.
No one had ever told me what happened after she left the study site.
"She is alive?" I asked.
My voice did not sound like mine.
"Her letter says she is alive and has recovered enough to decide what she wants to ask."
I closed my eyes once.
Relief was not innocence. Her survival did not make the altered records smaller. But a locked room inside me opened far enough to breathe.
After I was removed, I had called the study office eleven times. The first three calls reached people I knew. The next eight went to legal. Nathan eventually told me that further contact could be interpreted as interference with a participant.
I had believed him because protecting Leah mattered more than protecting myself.
Now Leah had needed her own lawyer to ask whether I approved what happened.
Celeste crossed her arms.
"Sterling maintained appropriate contact through the study team."
Rhea's expression cooled. "Her attorney disputes that description."
Nathan asked for the letter.
"No," Rhea said. "Not until the board adopts a confidentiality protocol that excludes public relations and limits distribution."
"I am chief legal officer."
"And your name appears in the missing file's custody history."
He sat back.
The audit chair ordered Ms. Vale to create a restricted record. Celeste objected to being excluded from material involving her own program.
"It was my program then," I said.
"And look what happened."
The sentence came too quickly. My father glanced at her, but she did not take it back.
I could have answered with the new timeline. I could have reminded her that my access ended before the record changed.
Leah's privacy mattered more than winning that minute.
"Follow her conditions," I told Rhea.
My father rose as if the patient inquiry were an interruption he could delegate.
"Sit down, Conrad," the audit chair said.
He looked at her for a long moment, then returned to his chair. It was the first direct order I had ever seen him obey inside Sterling Biotech.
The letter appeared only on the audit chair's secure tablet. She read it silently, then authorized one paragraph to be read aloud.
Rhea used Leah's exact words.
Five years earlier, a company representative had told her that Dr. Evelyn Sterling personally approved a revised study plan. Leah had later seen a public statement saying the same thing. She now wanted confirmation from an independent source.
I gripped the edge of my chair.
I had never approved a revised plan.
I had recommended a pause.
My father stared at the table. Nathan looked at the restricted-record notice. Celeste reached for the crown and then seemed to realize what she was doing.
Rhea read Leah's final authorized sentence.
"I am not asking who is sorry. I am asking who changed the form."